ABBV
ABBV
Indicative, may be delayed. Not trading-grade data.
Recently viewed
Only on this browser · up to 5Ticker detail
ABBV
Cached quote, historical USD prices, and attributed headlines.
AI-generated
AI overview
Latest ABBV headlines
- AbbVie's earnings doubled as its immunology drug Skyrizi continued to beat expectations [5]. - Recent coverage examines key takeaways for long-term investors and whether the stock is a buy following its latest earnings report [1][2]. - Analysis discusses how an earnings beat may alter the investment case for AbbVie stock [3]. - A Q3 2026 earnings call transcript is available [4].
Generated Nov 01, 2026 · 11:43 UTC
- AbbVie: 3 Key Takeaways for Long-Term Investors — Yahoo Finance
- Is AbbVie a Buy After Its Latest Earnings Report? — Yahoo Finance
- Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)? — Yahoo Finance
- AbbVie (ABBV) Q3 2026 Earnings Call Transcript — Yahoo Finance
- AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again — Yahoo Finance
Summary of the linked headlines, not full-article analysis. AI can make mistakes; verify the sources. Not investment advice.
Some history or news is missing or stale. Available cached data remains visible; background requests respect provider retry backoff. Reload this range to check again.
Historical price
251 observations · USD · Source: Yahoo Finance · Oct 31, 2025 · 13:30 UTC to Oct 30, 2026 · 13:30 UTC · latest observation may be incomplete.
News about ABBV
- AbbVie: 3 Key Takeaways for Long-Term Investors ↗
- Is AbbVie a Buy After Its Latest Earnings Report? ↗
- Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)? ↗
- AbbVie (ABBV) Q3 2026 Earnings Call Transcript ↗
- AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again ↗
- Q3 earnings round-up: AstraZeneca, AbbVie, Kenvue ↗
- LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today ↗
- What AbbVie (ABBV) Said on Its Q3 Earnings Call ↗
- AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views ↗
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends ↗
- ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View ↗
- CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend. Which Should Retirees Choose? ↗
- Pre-Markets Spooked on Questions Regarding AI, Oil Prices ↗
- Stock Market Today: Nasdaq Futures Plunge 2% as Big Tech Sells Off ↗
- AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates ↗
- Since HDV Switched to Monthly Pay, Here’s What’s Changed for Income Investors ↗
- Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings ↗
- AbbVie beats estimates but stock dips ↗
- AbbVie Is Up 10% in a Month to a 52-Week High: Is There “More Room for Multiple Expansion”? ↗
- AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates ↗
Comments and bookmarks
Comments are plain text from NPDev accounts. Bookmarks stay private to the account that saved them.
No comments yet. Be the first to say something.
Sign in to join the conversation.